Steven Schoenfeld - Concepedia

Concepedia

Author

Steven Schoenfeld

University of California, San Francisco

Also Known As

Steven L Schoenfeld, Steven L. Schoenfeld, Steven Schoenfeld

23

Publications

1.3K

Citations

12

H-Index

40

Concepts

All Affiliations

University of California, San Francisco Memorial Sloan Kettering Cancer Center University of California, Los Angeles Duke Medical Center The University of Texas Southwestern Medical Center

SS

About

Steven Schoenfeld is an author at University of California, San Francisco specializing in medicine, pathology, and glioma.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	360
2	Neurology	3	3	72
3	Health Sciences	1	1	24
4	Diabetes	1	1	85
5	Immunology	1	1	85

Steven Schoenfeld

×

13

Publications

1.3K

Citations

12

H-Index

	Year	Citations
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma Ingo K. Mellinghoff, Martin J. van den Bent, Deborah T. Blumenthal, New England Journal of Medicine	2023	606
Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial Ingo K. Mellinghoff, Min Lu, Patrick Y. Wen, Nature Medicine	2023	191
Cyclical Etidronate in the Treatment of Postmenopausal Osteoporosis Paul D. Miller, Nelson B. Watts, Angelo A. Licata, The American Journal of Medicine Bone HealthGynecologyMenopauseMedicineCyclical Etidronate	1997	153
Pramlintide, a Synthetic Analog of Human Amylin, Improves the Metabolic Profile of Patients With Type 2 Diabetes Using Insulin Robert G. Thompson, Leeanne L. Pearson, Steven Schoenfeld, Diabetes Care	1998	86
Nonprogression of Subclinical β-Cell Dysfunction Among First-Degree Relatives of IDDM Patients: 5-Yr Follow-Up of the Seattle Family Study David K. McCulloch, Leslie J. Klaff, Steven E. Kahn, Diabetes Subclinical β-Cell DysfunctionGenetic EpidemiologyImmunologyPathologyGlucose Potentiation	1990	85
Systematic Variation and Differences in Insulin-Autoantibody Measurements Terence J. Wilkin, Steven Schoenfeld, José-Luis Dı́az, Diabetes	1989	37
Phase 1 study of AG-881, an inhibitor of mutant IDH1/IDH2, in patients with advanced IDH-mutant solid tumors, including glioma. Ingo K. Mellinghoff, Marta Peñas-Prado, Katherine B. Peters, Journal of Clinical Oncology PathologyPharmacotherapyHigh-grade GliomasGliomaTumor Biology	2018	35
A phase I, open label, perioperative study of AG-120 and AG-881 in recurrent IDH1 mutant, low-grade glioma: Results from cohort 1. Ingo K. Mellinghoff, Timothy F. Cloughesy, Patrick Y. Wen, Journal of Clinical Oncology Recurrent Idh1 MutantPlasma RatiosPathologyPharmacotherapyHigh-grade Gliomas	2019	33
ACTR-66. A PHASE 1, OPEN-LABEL, PERIOPERATIVE STUDY OF IVOSIDENIB (AG-120) AND VORASIDENIB (AG-881) IN RECURRENT IDH1 MUTANT, LOW-GRADE GLIOMA: UPDATED RESULTS Ingo K. Mellinghoff, Timothy F. Cloughesy, Patrick Y. Wen, Neuro-Oncology Ivo 10PathologyPharmacotherapyHigh-grade GliomasBrain Lesion	2019	24
Non-Hodgkin’s Lymphoma of the Central Nervous System after Treatment of Hodgkin’s Disease Douglas C. Miller, Robert Knee, Steven Schoenfeld, American Journal of Clinical Pathology	1989	18

Page 1